Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

foscenvivint (PRI724)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ohara Pharma, PRISM Pharma

Drug class:

CBP inhibitor, β-catenin inhibitor, Wnt signalling pathway inhibitor

Related drugs:

CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B
CTNNB1 expression	Hepatocellular Cancer	CTNNB1 expression	Hepatocellular Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
RBMS3 deletion	Ovarian Cancer	RBMS3 deletion	Ovarian Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
BOP1 overexpression	Triple Negative Breast Cancer	BOP1 overexpression	Triple Negative Breast Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
CTNNB1 S45P	Hepatocellular Cancer	CTNNB1 S45P	Hepatocellular Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D